Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

被引：2
作者：
Revuelta-Herrero, J. L. [1 ]
Gimenez-Manzorro, A. [1 ]
Matilla-Pena, A.
Herranz-Alonso, A. [1 ,2 ]
Sanjurjo-Saez, M. [1 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Pharm Dept, IiSGM, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Gastroenterol Dept, IiSGM, Madrid, Spain
来源：
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2018年 / 43卷 / 06期
关键词：
antiviral agents; drug interaction; hepatitis C; hepatocellular carcinoma; sorafenib; HEPATOCELLULAR-CARCINOMA; EVENTS; HCC;
D O I：
10.1111/jcpt.12727
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
What is known and objective No studies have evaluated the use of sorafenib with the direct-acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV). Case summaryWhat is new and conclusionThree hepatitis C virus genotype 1b-infected patients with well-preserved liver function were included in this prospective case series. The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV/PTV/r+DSV for 12weeks. One patient discontinued sorafenib while concomitant treatment due to grade 2 fatigue and muscular pain. The other two patients reported only grade 1 adverse effects. Sustained virologic response at 24weeks was achieved, and no tumour recurrences were found. The concurrent use of OBV/PTV/r+DSV with sorafenib was considered safe and effective.
引用
收藏
页码：906 / 909
页数：4
相关论文
共 50 条
  • [1] Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice
    Gonzalez-Colominas, Elena
    Londono, Maria-Carlota
    Morillas, Rosa M.
    Torras, Xavier
    Mojal, Sergi
    Lens, Sabela
    Lopez, Dulce
    Gallego, Adolfo
    Marino, Zoe
    Ardevol, Merce
    Pages, Neus
    Sola, Ricard
    Carrion, Jose A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (05) : 1100 - 1107
  • [2] Efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir+ Dasabuvir and Ribavirin in patients with compensated HCV cirrhosis
    Crisu, Georgiana C.
    Ionita-Radu, Florentina
    Costache, Raluca S.
    Balaban, Vasile D.
    Nuta, Petrut
    Stoica, Victor
    Vutcan, L. Oana
    Stefan, Ion
    Naftanaila, Florica Mali
    Jinga, Mariana
    ROMANIAN JOURNAL OF MILITARY MEDICINE, 2019, 122 (01) : 22 - 26
  • [3] Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice
    Chamorro-de-Vega, Esther
    Gimenez-Manzorro, Alvaro
    Guadalupe Rodriguez-Gonzalez, Carmen
    Escudero-Vilaplana, Vicente
    Collado Borrell, Roberto
    Ibanez-Garcia, Sara
    Lallana Sainz, Elena
    Lobato Matilla, Elena
    Lorenzo-Pinto, Ana
    Manrique-Rodriguez, Silvia
    Fernandez-Llamazares, Cecilia M.
    Marzal-Alfaro, MariaBelen
    Ribed, Almudena
    Romero Jimenez, Rosa Maria.
    Sarobe Gonzalez, Camino
    Herranz, Ana
    Sanjurjo, Maria
    ANNALS OF PHARMACOTHERAPY, 2016, 50 (11) : 901 - 908
  • [4] Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin
    Manea, E. D.
    Stefan, I
    Olariu, C.
    Calina, O. C.
    Jipa, R. E.
    Hristea, A.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2018, 81 (01) : 9 - 13
  • [5] Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma
    Krastev, Zahariy
    Jelev, Deian
    Antonov, Krasimir
    Petkova, Tanya
    Atanasova, Evelina
    Zheleva, Nadezhda
    Tomov, Bojidar
    Boyanova, Yana
    Mateva, Lyudmila
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (08) : 2630 - 2635
  • [6] OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS
    Bayan, Kadim
    Celen, Mustafa Kemal
    Dal, Tuba
    Ayaz, Celal
    Tekin, Recep
    Akdemir, Irem
    Sari, Tugba
    Gunal, Ozgur
    Efe, Savas Cumali
    ACTA MEDICA MEDITERRANEA, 2018, 34 (01): : 71 - 75
  • [7] Ombitasvir/paritaprevir/ritonavir plus dasabuvir plus /- ribavirin in real world hepatitis C patients
    Loo, Nicole
    Lawitz, Eric
    Alkhouri, Naim
    Wells, Jennifer
    Landaverde, Carmen
    Coste, Angie
    Salcido, Rossalynn
    Scott, Michael
    Poordad, Fred
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (18) : 2229 - 2239
  • [8] Severe Hepatotoxicity of Ritonavir, Ombitasvir, Paritaprevir, and Dasabuvir in a Kidney Transplant Recipient
    Bukal, Nikolina
    Furic-Cunko, Vesna
    Juric, Ivana
    Katalinic, Lea
    Dedo, Antonia
    Basic-Jukic, Nikolina
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2019, 30 (05) : 1184 - 1186
  • [9] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis
    Pessoa, Mario G.
    Ramalho-Madruga, Jose, V
    Alves, Katia
    Nunes, Estevao P.
    Cheinquer, Hugo
    Brandao-Mello, Carlos E.
    Mendes-Correa, Maria C.
    Ferraz, Maria L.
    Ferreira, Paulo R. A.
    Alvares-da-Silva, Mario R.
    Coelho, Henrique S.
    Affonso-de-Araujo, Evaldo S.
    Furtado, Juvencio
    Parana, Raymundo
    Silva, Giovanni
    Lari, Sara A.
    Liu, Li
    Tripathi, Rakesh
    Pilot-Matias, Tami
    Cohen, Daniel E.
    Shulman, Nancy S.
    Martinelli, Ana
    ANNALS OF HEPATOLOGY, 2018, 17 (06) : 959 - 968
  • [10] Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
    Bernstein, David E.
    Tran, Albert
    Martin, Paul
    Kowdley, Kris V.
    Bourliere, Marc
    Sulkowski, Mark S.
    Pockros, Paul J.
    Renjifo, Boris
    Wang, Deli
    Shuster, Diana L.
    Cohen, Daniel E.
    Jacobson, Ira M.
    KIDNEY INTERNATIONAL REPORTS, 2019, 4 (02): : 245 - 256
12345